cialis online viagra bestellen kamagra jelly kamagra oral jelly kamagra australia cialis australia levitra australia cialis générique viagra générique cialis 20 mg cialis prijs cialis kopen viagra voor vrouwen kamagra kopen viagra prijs viagra kvinder viagra online køb viagra køb viagra cialis piller viagra uden recept

Unique drug candidate APR-246 boosts cancer treatment
Aprea’s drug candidate has anti-tumor effects and may also fulfill an unmet need by overcoming resistance to several conventional chemotherapeutic drugs.
p53 is key to cancer treatment
Many anticancer drugs work by inducing DNA damage in cancer cells. This activates the tumor suppressor protein p53, which triggers cellular aging and/or cell death by apoptosis, thus eliminating the tumor. But 50% of all tumors carry mutant defective p53 that fails to induce cell death. These tumors often show increased resistance to chemotherapy and poor prognosis.
APR-246 repairs p53
Aprea has found a unique way of putting defective p53 back into shape. Aprea’s drug candidate APR-246 reactivates both mutant and defective native p53, leading to tumor cell death. This also raises hopes for improving the efficacy of chemotherapy. Initial clinical trials have shown good safety and significant biological and clinical effects.
> Read more about Aprea’s R&D program